NeuroMetrix, Inc. (NASDAQ:NURO) Sees Significant Growth in Short Interest

NeuroMetrix, Inc. (NASDAQ:NURO) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 22,500 shares, an increase of 67.9% from the September 15th total of 13,400 shares. Based on an average trading volume of 19,300 shares, the short-interest ratio is currently 1.2 days. Approximately 1.6% of the company’s stock are sold short.

NeuroMetrix Stock Down 2.2 %

Shares of NASDAQ:NURO opened at $4.06 on Monday. The business’s 50 day moving average is $3.75 and its 200 day moving average is $3.85. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $5.60. The stock has a market cap of $8.16 million, a price-to-earnings ratio of -0.64 and a beta of 2.29.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings data on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share (EPS) for the quarter. The firm had revenue of $0.77 million for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of NeuroMetrix in a research report on Friday. They issued a “sell” rating on the stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.